The<unk> <unk>  trial compared major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.  No significant difference was observed on CHD mortality in the group treated with pravastatin 40 mg daily as compared to the usual care group with well controlled hypertension and moderately elevated LDL. Possible explanations for failure to observe a significant reduction included a modest reduction in total cholesterol, unblinded study with no placebo group and a large crossover of high risk subjects
Antihypertensive and lipid-lowering treatment to prevent heart attack trial
Cardiac resynchronization therapy landmark trials
Atrial fibrillation cost-effectiveness of therapy
Chronic stable angina treatment lipid management
Chronic stable angina exercise echocardiography
Chronic stable angina risk assessment in patients with an intermediate or high probability of coronary artery disease
Chronic stable angina COURAGE trial
Chronic stable angina medical therapy